CenterBook Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$27.7M Sell
23,135
-6,121
-21% -$6.25M 1.36% 11
2026
Q1
$26.9M Buy
29,256
+4,785
+20% +$4.85M 1.45% 6
2025
Q4
$26.3M Buy
+24,471
New +$23.4M 1.29% 7
2025
Q3
Sell
-34,345
Closed -$26.8M 615
2025
Q2
$26.8M Buy
+34,345
New +$26.7M 1.49% 10
2025
Q1
Sell
-19,306
Closed -$14.9M 547
2024
Q4
$14.9M Buy
19,306
+17,222
+826% +$14.3M 0.89% 17
2024
Q3
$1.85M Sell
2,084
-6,629
-76% -$5.96M 0.11% 203
2024
Q2
$7.89M Buy
8,713
+525
+6% +$420K 0.49% 49
2024
Q1
$6.37M Buy
+8,188
New +$5.83M 0.44% 63
2023
Q4
Sell
-2,976
Closed -$1.6M 448
2023
Q3
$1.6M Sell
2,976
-832
-22% -$429K 0.2% 176
2023
Q2
$1.79M Sell
3,808
-2,854
-43% -$1.2M 0.22% 162
2023
Q1
$2.29M Sell
6,662
-1,117
-14% -$377K 0.32% 99
2022
Q4
$2.85M Buy
7,779
+2,769
+55% +$982K 0.47% 50
2022
Q3
$1.62M Sell
5,010
-1,777
-26% -$563K 0.31% 104
2022
Q2
$2.2M Buy
+6,787
New +$2.04M 0.47% 52

Other funds holding LLY

CenterBook Partners's LLY Position: Q2 2026 in Review

CenterBook Partners reduced its Eli Lilly (LLY) stake by 21% in Q2 2026, selling an estimated $6.25M and leaving 23,135 shares worth $27.7M. The position accounts for 1.36% of the portfolio, ranked #11.

CenterBook Partners first reported a position in LLY in Q2 2022 and has held it in 14 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • CenterBook Partners held 23,135 shares of Eli Lilly worth $27.7M as of Q2 2026.
  • CenterBook Partners sold 6,121 Eli Lilly shares in Q2 2026, an estimated $6.25M.
  • Eli Lilly made up 1.36% of CenterBook Partners's portfolio in Q2 2026, its #11 holding.
  • CenterBook Partners first reported a position in Eli Lilly in Q2 2022 and has held it in 14 quarters since.
  • 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.